Does inhibition of NLRP3 prevent atrial fibrillation?
Inhibition of the NLRP3 inflammasome in cardiomyocytes represents a potential novel therapeutic approach for atrial fibrillation.
Our study establishes a novel pathophysiological role for CM NLRP3 inflammasome signaling, with a mechanistic link to the pathogenesis of AF, and establishes the inhibition of NLRP3 as a potential novel AF therapy approach.
Yao et al. (Fri,) studied this question.